PDCD1 and triple-negative breast carcinoma: Given the recent preclinical and clinical studies, focusing on combination therapies of DOX and PD1-PDL1 inhibitors, especially in triple-negative breast cancer, reliable data for adverse effect risk assessment are urgently needed [26,29,30].